Apatorsen - Ionis Pharmaceuticals
Alternative Names: ISIS-306053; OGX-427Latest Information Update: 02 Oct 2021
At a glance
- Originator Ionis Pharmaceuticals; University of British Columbia
- Developer Achieve Life Sciences; Queen Mary Medical School; Sarah Cannon Research Institute
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action HSP27 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Bladder cancer
Highest Development Phases
- Discontinued Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
Most Recent Events
- 01 Oct 2017 Hoosier Cancer Research Network completes the phase II Borealis-2 trial for Bladder cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT01780545)
- 21 Jun 2017 Hoosier Cancer Research Network terminates a phase II trial in Prostate Cancer (Combination therapy, Metastatic disease) in USA and Canada due to lack of accrual (NCT01681433)
- 05 May 2017 Sarah Cannon Research Institute and OncoGenex Pharmaceuticals completes the phase II Spruce™ trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (NCT01829113)